Dr. Matthew Walker -- Pharmaceutical Payment Report
This page provides a comprehensive transparency report for Dr. Matthew Walker, a Oncology physician based in Princeton, NJ. All payment data is sourced from the CMS Open Payments (Sunshine Act) database. Dr. Matthew Walker has received $25,917.23 in total pharmaceutical industry payments across 1 transactions from 1 pharmaceutical companies.
Physician Profile
The following profile information is sourced from the National Provider Identifier (NPI) registry and CMS Open Payments records.
- Full Name: Dr. Matthew Walker
- Medical Specialty: Oncology
- Practice Location: Princeton, NJ, New Jersey
- NPI Number: 1537348424
- Transparency Score: 50/100
- Payment Records Span: 2024-05-24 to 2024-05-24
Payment Summary
Dr. Matthew Walker has received a total of $25,917.23 in pharmaceutical industry payments across 1 recorded transactions in the CMS Open Payments database. The average payment amount is $25,917.23 per transaction.
- Total Payments Received: $25,917.23
- Number of Transactions: 1
- Average Payment: $25,917.23
- Transparency Score: 50/100 -- This score reflects the overall payment profile relative to peers in Oncology. A higher score indicates fewer or more routine payments.
- Number of Pharma Relationships: 1 pharmaceutical companies
- Drugs/Devices Referenced: 1 distinct products
Payment Breakdown by Category
The following table shows how Dr. Matthew Walker's pharmaceutical payments break down by payment category. Understanding the mix of payment types provides important context about the nature of the doctor-pharma relationship.
| Payment Category | Amount | Description |
|---|---|---|
| Consulting Fees | $25,917.23 | Advisory board participation, clinical consulting, and expert opinion services |
The largest payment category for Dr. Matthew Walker is Consulting Fees, accounting for 100% ($25,917.23) of total pharmaceutical payments received. This suggests active involvement in pharmaceutical company advisory and educational programs.
Pharmaceutical Company Relationships
The following pharmaceutical and medical device companies have made payments to Dr. Matthew Walker. Click on any company name to view their full physician payment profile and spending patterns.
| Company | Total Paid | Transactions |
|---|---|---|
| Roche/Genentech | $25,917.23 | 1 |
Dr. Matthew Walker has a financial relationship with Roche/Genentech, receiving $25,917.23 in total. Having a single pharmaceutical company relationship means all payments come from one source, which may indicate a focused consulting or research relationship.
Drugs and Medical Devices Referenced in Payments
The following drugs and medical devices have been referenced in pharmaceutical payments to Dr. Matthew Walker. These references indicate that the payment was related to the marketing, consulting, or clinical use of these products.
- Wegovy -- Referenced in payment records from pharmaceutical companies to Dr. Matthew Walker
The presence of a drug or device in a payment record means the pharmaceutical company associated the payment with that product. This is common for consulting fees related to a specific medication, speaking engagements about a product, or research involving a particular drug or device.
AI Transparency Analysis
The following analysis was generated by artificial intelligence based on Dr. Matthew Walker's payment history, specialty peer comparisons, and payment pattern analysis. This analysis is not medical or legal advice.
Matthew Walker has received $25.9K across 1 pharmaceutical payments as a Oncology physician in Princeton, NJ. Top paying companies include Roche/Genentech ($25.9K). The physician received a single payment of $25,917 in 2024. This payment was from Roche/Genentech and categorized as consulting. The payment is associated with the drug Wegovy.
Patient Guidance: Questions to Ask Your Doctor
If Dr. Matthew Walker is your physician, here is practical guidance on how to understand and discuss pharmaceutical industry relationships:
Consumers should consider that a single, large payment might represent a specific consulting engagement or research project, and may not reflect ongoing financial relationships. Always feel free to ask your doctor directly about their pharmaceutical relationships.
Peer Comparison: How Dr. Matthew Walker Compares to Other Oncology Physicians
As an Oncologist, this physician's payment profile is relatively low in volume compared to peers who may engage in more frequent research or consulting activities.
Recent Payment Records
The following table shows the most recent pharmaceutical industry payments recorded for Dr. Matthew Walker in the CMS Open Payments database. Click on any payment to view the full report.
| Company | Amount | Type | Drug/Device | Date | Conflict Level |
|---|---|---|---|---|---|
| Roche/Genentech | $25,917.23 | consulting | Wegovy | 2024-05-24 | Not Assessed |
Frequently Asked Questions About Dr. Matthew Walker's Pharma Payments
Below are common questions patients ask about physician pharmaceutical payment data.
How much pharma money has Matthew Walker received?
Matthew Walker has received a total of $25.9K across 1 payments from pharmaceutical companies. This data is publicly reported under the CMS Open Payments (Sunshine Act) program.
Is Matthew Walker taking too much pharma money?
Matthew Walker has received $25.9K in pharmaceutical payments. Whether this is "too much" depends on the physician's specialty (Oncology), the types of payments, and how they compare to peers. The largest payment category is consulting ($25.9K). Payment does not imply wrongdoing, but patients should be aware and can ask their doctor directly.
What pharma companies pay Matthew Walker?
The top pharmaceutical companies paying Matthew Walker are: Roche/Genentech ($25.9K). These payments cover various categories including consulting, meals, speaking fees, and research grants.
What kinds of payments does Matthew Walker receive?
Matthew Walker's payments by type: consulting: $25.9K. Consulting fees suggest active advisory roles with pharmaceutical companies.
Should I switch doctors because of pharma payments?
Pharma payments alone are not typically reason to switch doctors. Many payments are routine (like meals at educational events) and do not indicate compromised care. Focus on: (1) whether your doctor explains treatment options clearly, (2) whether generic alternatives are discussed, (3) the overall pattern of payments, not individual transactions. If you have concerns, ask your doctor directly.
How do Matthew Walker's payments compare to other Oncology doctors?
To compare, look at the total amount ($25.9K), number of payments (1), and the types of payments received. Oncology physicians may receive different payment amounts depending on subspecialty, geographic location, and academic affiliation. Use CMS Open Payments data to compare across the specialty.
How can I verify Matthew Walker's payment data?
You can verify this data directly through the CMS Open Payments database at openpaymentsdata.cms.gov. Search by physician name or NPI number (1537348424). All data is reported by pharmaceutical companies and verified by CMS. DoctorPharmaData aggregates this public data for easier access.
Do pharma payments affect prescribing quality?
Research published in JAMA Internal Medicine and other peer-reviewed journals shows a statistical association between pharmaceutical payments and prescribing patterns. However, correlation does not equal causation. Many physician-industry interactions are legitimate (research, education, advisory boards). The Sunshine Act was created to promote transparency so patients can make informed decisions.
What stands out about Matthew Walker's pharma payment profile?
The physician has a single payment, making it difficult to establish a trend. Matthew Walker has received $25.9K in total pharma payments.
How does Matthew Walker compare to peers in Oncology?
As an Oncologist, this physician's payment profile is relatively low in volume compared to peers who may engage in more frequent research or consulting activities.
Are Matthew Walker's pharma relationships typical for Oncology?
The entire payment amount comes from one company, indicating high company concentration.
What should patients of Matthew Walker know about these payments?
Consumers should consider that a single, large payment might represent a specific consulting engagement or research project, and may not reflect ongoing financial relationships.
What patterns are visible in Matthew Walker's payment history?
The payment is linked to a specific drug, Wegovy, which may suggest a focus on that therapeutic area.
Understanding This Doctor Payment Report
This transparency report for Dr. Matthew Walker is based on data from the CMS Open Payments database, which is maintained by the Centers for Medicare and Medicaid Services under the Physician Payments Sunshine Act. Here are important things to understand:
- Payment does not imply wrongdoing. Many pharmaceutical payments represent legitimate professional activities such as consulting on drug development, speaking at medical education events, and conducting clinical research.
- Context matters. A large payment for conducting a clinical trial has very different implications than a large payment for promotional speaking. The payment breakdown by category above provides this context.
- Peer comparison is important. Whether a payment amount is unusual depends heavily on the physician's specialty, geographic location, and career stage. Oncology physicians may have very different payment norms than physicians in other fields.
- Data may be incomplete. The CMS Open Payments database captures payments from pharmaceutical and medical device manufacturers. It does not include payments from other sources, such as hospitals, insurance companies, or government agencies.
- Reporting thresholds apply. Small payments below certain thresholds may not be individually reported. The totals reflect payments above reporting minimums set by CMS regulations.
About the Physician Payments Sunshine Act
The Physician Payments Sunshine Act, enacted as Section 6002 of the Affordable Care Act in 2010, requires pharmaceutical and medical device companies to report payments and other transfers of value to physicians and teaching hospitals to CMS. This law was designed to increase transparency in the financial relationships between the healthcare industry and medical providers.
Under this law, Dr. Matthew Walker's pharmaceutical payments are publicly disclosed. The types of reportable transactions include consulting fees, compensated speaking or educational activities, honoraria, gifts, entertainment, food and beverages, travel and lodging, education or conference attendance, research grants, charitable contributions, royalties or licenses, current or prospective ownership interests, and direct compensation for services other than consulting.
The Open Payments data for Dr. Matthew Walker and all other physicians can be accessed at the official CMS Open Payments website.
Related Resources
- Oncology Specialty Payment Data -- See payment patterns for all oncology physicians
- New Jersey Physician Payments -- Browse pharmaceutical payments to physicians in New Jersey
- Oncology Physicians in New Jersey -- Compare Dr. Matthew Walker to peers in the same state and specialty
- Roche/Genentech Payment Profile -- View all payments made by Dr. Matthew Walker's largest pharmaceutical partner
- Search for Another Doctor or Company -- Look up any physician or pharmaceutical company in our database
- Official CMS Open Payments Database -- Verify payment data directly with the federal government
- NPI Registry -- Look up Dr. Matthew Walker's NPI (1537348424) in the official provider registry
Data from CMS Open Payments (Sunshine Act). Payment does not imply wrongdoing. AI analysis is not medical or legal advice. Consult your healthcare provider about any concerns.